NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 as compared with placebo. Statistically significant improvements were achieved in all key secondary endpoints in the trial as well. The safety profile was consistent with previous Phase 2 studies.
Trending
- Where GI practices are struggling, succeeding (Becker’s GI & Endoscopy)
- Physician shortage and private equity: the ruin of U.S. health care (KevinMD)
- Why leading physicians will move to concierge medicine in 2026 with Greg Grant of Specialdocs (Physicians Practice)
- Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy (Nature)
- Stiffer colon could signal risk of early-onset colorectal cancer (Medical Xpress)
- Successful GI Sign-off Protocol Incorporates Primary Care Feedback (GI & Endoscopy News)
- Earlier and More Intensive Advanced Therapy Use Fails to Improve 10-Year Crohn’s Outcomes (Docwire News)
- CMS Launches WISeR Model: New Medicare Prior Authorization Rules Start Jan. 1 (HIT Consultant)
